Samsung Bioepis's Biosimilar to be Sold in Europe
Samsung Bioepis's Biosimilar to be Sold in Europe
  • By Chun Go-eun (info@koreaittimes.com)
  • 승인 2016.01.18 17:54
  • 댓글 0
이 기사를 공유합니다

Samsung Bioepis said Sunday it is finally licensed to sell its biosimilar -- also known as follow-on biologic -- to the European market. It received the final approval from the European Commission. 
 
The company's benepali is now scheduled to have the last administrative procedure after receiving positive reviews from Committee for Medicinal Products for Human Use of European Medicines Agency in November.
 
Through the final approval, benepali is set to be available in 28 EU member nations and European Economic Area including Norway, Iceland and Liechtenstein. Benepali is etanercept biosimilar similar to Brenzys launched in December in the local market.
 
Samsung Bioepis received an approval for rheumarthritis, psoriatic arthritis and spondylarthritis.

댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • ABOUT
  • CONTACT US
  • SIGN UP MEMBERSHIP
  • RSS
  • 2-D 678, National Assembly-daero, 36-gil, Yeongdeungpo-gu, Seoul, Korea (Postal code: 07257)
  • URL: www.koreaittimes.com | Editorial Div: 82-2-578- 0434 / 82-10-2442-9446 | North America Dept: 070-7008-0005 | Email: info@koreaittimes.com
  • Publisher and Editor in Chief: Monica Younsoo Chung | Chief Editorial Writer: Hyoung Joong Kim | Editor: Yeon Jin Jung
  • Juvenile Protection Manager: Choul Woong Yeon
  • Masthead: Korea IT Times. Copyright(C) Korea IT Times, All rights reserved.
ND소프트